Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease

Clinical Neuropharmacology

Volumn 31, Issue 3, 2008, Pages 134-140

  Müller, Thomas ^a   Kolf, Kira ^a   Ander, Lema ^a   Woitalla, Dirk ^a   Muhlack, Siegfried ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Entacapone; Grip strength; Levodopa; Parkinson disease; Retarded release

Indexed keywords

3 O METHYLDOPA; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA; RASAGILINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; DRUG RESPONSE; DYSKINESIA; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BLOOD-BRAIN BARRIER; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HAND STRENGTH; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MUSCLE STRENGTH; NITRILES; PARKINSON DISEASE; PSYCHOMOTOR DISORDERS; SEVERITY OF ILLNESS INDEX; TYROSINE;

EID: 44649151773     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31811510ed     Document Type: Article

References (24)

1. Fellows SJ, Noth J. Grip force abnormalities in de novo Parkinson's disease. Mov Disord 2004;19:560-565.
2. Müller T, Schäfer S, Kuhn W, et al. Correlation between tapping and inserting of pegs in Parkinson's disease. Can J Neurol Sci 2000;27:311-315.
3. Fellows SJ, Noth J, Schwarz M. Precision grip and Parkinson's disease. Brain 1998;121(pt 9):1771-1784.
4. Gordon AM, Ingvarsson PE, Forssberg H. Anticipatory control of manipulative forces in Parkinson's disease. Exp Neurol 1997;145:477-488.
5. Brown P, Corcos DM, Rothwell JC. Does parkinsonian action tremor contribute to muscle weakness in Parkinson's disease? Brain 1997;120(pt 3):401-408.
6. Wenzelburger R, Zhang BR, Pohle S, et al. Force overflow and levodopa-induced dyskinesias in Parkinson's disease. Brain 2002;125:871-879.
7. Lou JS, Kearns G, Benice T, et al. Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study. Mov Disord 2003;18:1108-1114.
8. Ziv I, Avraham M, Michaelov Y, et al. Enhanced fatigue during motor performance in patients with Parkinson's disease. Neurology 1998;51:1583-1586.
9. Merkies IS, Schmitz PI, Samijn JP, et al. Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies. Muscle Nerve 2000;23:1393-1401.
10. Goetz CG, LeWitt PA, Weidenman M. Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord 2003;18:1455-1458.
11. Block G, Liss C, Reines S, et al. The CR First Study Group. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. Eur Neurol 1997;37:23-27.
12. Koller WC, Hutton JT, Tolosa E, et al. Carbidopa/Levodopa Study Group. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999;53:1012-1019.
13. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
14. Kaakkola S, Teravainen H, Ahtila S, et al. Entacapone in combination with standard or controlled-release levodopa carbidopa - a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 1995;2:341-347.
15. Piccini P, Brooks DJ, Korpela K, et al. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68:589-594.
16. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
17. Müller T, Erdmann C, Muhlack S, et al. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. J Neural Transm 2006;113:1441-1448.
18. Keranen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993;16:145-156.
19. Baas H, Zehrden F, Selzer R, et al. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Clin Pharmacokinet 2001;40:383-393.
20. Benetello P, Furlanut M, Fortunato M, et al. Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association. Pharmacol Res 1997;35:313-315.
21. Mannisto PT, Tuomainen P, Toivonen M, et al. Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats. J Neural Transm Park Dis Dement Sect 1990;2:31-43.
22. Guttman M, Leger G, Cedarbaum JM, et al. 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 1992;31:638-643.
23. Busa WB, Nuccitelli R. Metabolic regulation via intracellular pH. Am J Physiol 1984;246:R409-R438.
24. Katz A, Sahlin K. Regulation of lactic acid production during exercise. J Appl Physiol 1988;65:509-518.